Corporate Logo(source: duchembio.com)
Radiopharmaceutical company DuchemBio announced on the 11th that it submitted a securities registration statement to the Financial Services Commission on the 8th to pursue a listing transfer to KOSDAQ.
Currently listed on the KONEX market, DuchemBio is planning an initial public offering(IPO) of 1.43 million shares, with a target offering price of 12,300 to 14,100 won per share.
A demand forecasting process for institutional investors is scheduled from November 20 to 26 to finalize the offering price, followed by a public subscription period on December 2-3. NH Investment & Securities is the lead underwriter.
DuchemBio, a subsidiary of pharmaceutical distributor Geo-Young, holds over 90% market share in the Alzheimer’s diagnostic agent market in South Korea.
Proceeds from the listing will be allocated toward manufacturing facility investments for diagnostics and therapeutics, debt repayment, R&D, and general working capital.
A representative of DuchemBio stated, “This listing aims to position DuchemBio as a leading global radiopharmaceutical company, extending beyond the domestic market. We are committed to achieving a successful KOSDAQ listing.”
Corporate Logo(source: duchembio.com)
Radiopharmaceutical company DuchemBio announced on the 11th that it submitted a securities registration statement to the Financial Services Commission on the 8th to pursue a listing transfer to KOSDAQ.
Currently listed on the KONEX market, DuchemBio is planning an initial public offering(IPO) of 1.43 million shares, with a target offering price of 12,300 to 14,100 won per share.
A demand forecasting process for institutional investors is scheduled from November 20 to 26 to finalize the offering price, followed by a public subscription period on December 2-3. NH Investment & Securities is the lead underwriter.
DuchemBio, a subsidiary of pharmaceutical distributor Geo-Young, holds over 90% market share in the Alzheimer’s diagnostic agent market in South Korea.
Proceeds from the listing will be allocated toward manufacturing facility investments for diagnostics and therapeutics, debt repayment, R&D, and general working capital.
A representative of DuchemBio stated, “This listing aims to position DuchemBio as a leading global radiopharmaceutical company, extending beyond the domestic market. We are committed to achieving a successful KOSDAQ listing.”